Abstract: A bottle support shoe receives a closed end of a medicine bottle to stabilize and inhibit slippage of a medicine bottle, and to hold the bottle upright. The shoe comprises a plate having a superior face defined by a convex shape that creates suction, and a mount face defined by a concave shape that creates suction. An interior sidewall extends from the plate at an angle between 44 degrees to 110 degrees, such that engaging the superior face with the closed end of bottle creates air space between the interior sidewall and the superior face. Engaging the mount face with a ground surface decreases and maintains air space between the interior sidewall and the mount face. An exterior sidewall circumambulates the interior sidewall. A bridge extends from interior sidewall to exterior sidewall. A grip panel overlays the mount face to further prevent slippage of the shoe.

Abstract: A medical connector includes a body having a distal end, a proximal end, and a sidewall extending between the distal end and the proximal end, a helical thread extending radially outward from a surface of the sidewall and comprising a crest portion, flank portions, and a root portion with the flank portions connecting the root portion to the crest portion, and at least one micro-thread extending radially outward from the surface of the sidewall. At least a portion of the micro-thread is spaced apart from the helical thread.

Abstract: A device for dispensing articles, the device comprising: a conveying member comprising n receptacles, of which n?m are suitable for receiving articles, the receptacles being movable between an article receiving position and an article dispensing position; a sensor for sensing the presence of articles in the receptacles, the sensor positioned between the receiving position and the dispensing position; wherein m of said receptacles is a blank receptacle which is unable to receive an article and the sensor is unable to distinguish an empty receptacle from a blank receptacle such that the maximum number of detectable articles conveyed once n receptacles have passed the sensor is n?m, where m is at least 1.

Abstract: Two embodiments of a cuspidor funnel are described, each of which may be securely attached to an empty beverage container, and then detached from the container with the container being disposed of after use. A first is attached to a standard sized beverage can while the second is structured to be attached to a standard sized beverage bottle. The can embodiment includes a cylindrical structure that snaps onto the beverage can top rim and positions a funnel neck into the opening of the beverage can typical of a press-tab opening soda or beer can. This funnel neck receives fluid captured by the angled funnel wall formed on the top face of the cuspidor funnel. The beverage bottle embodiment includes a generally cylindrical structure that is threaded onto the beverage bottle opening typical of most single serving plastic beverage bottle containers.

Abstract: Cosmetic composition for lightening the color of keratinic fibers, including at least two separately packaged formulations (A) and (B) which are mixed immediately prior to application to give an application mixture, wherein the formulation (A), based on its total weight, contains from about 10% to about 99% by weight of peroxodisulfate(s), and the formulation (B) is a free-flowing composition comprising water and at least one oxidizing agent, characterized in that the formulation (A) has been packaged in a water-soluble film including, based on its total weight, at least about 60% by weight of a polymer mixture having a multimodal molecular weight distribution, feature above-average application properties.

Abstract: A toothpaste comprising at least 5% sodium chloride and a carrageenan-based binder, having high antibacterial efficacy, very stable viscosity and excellent striping properties, together with methods and uses therefore.

Abstract: A process for manufacture of an antiperspirant composition comprising the reaction of an aqueous solution of aluminum sesquichlorohydrate, water soluble calcium salt and amino acid, at a total anhydrous solids content of from 33 to 60% by weight and at a temperature of at least 65° C., for a period of from 1 to 24 hours, wherein the molar ratio of water soluble calcium salt to aluminum sesquichlorohydrate is at least 1:40 and the molar ratio of amino acid to aluminum sesquichlorohydrate is at least 1:20, the mixture then being cooled to less than 25° C. and diluted with at least an equal weight of water or to a total anhydrous solids content of less than 31% by weight, the dilution phase being performed within 10 days of cooling phase.

Abstract: Provided herein is a method for removing a chemical stain from a dental surface or inhibiting chemical staining of a dental surface, comprising contacting the dental surface with an oral care composition comprising zinc phosphate and an orally acceptable carrier.

Abstract: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a bodywash, shampoo, conditioner, lotion, gel, soap, cream, hand sanitizer, spray or mousse and can be used by an individual during their normal hygiene processes, such as during a shower or bath or while applying a body product to their skin or hair.

Abstract: Described herein are packages for storing and dispensing multi-part tooth whitening formulations, comprising a deformable material configured to form two or more sealed chambers, e.g., wherein the first chamber contains a low viscosity liquid solution comprising an enzyme having perhydrolytic activity, and the second chamber contains a peroxide source and a at least one acyl donor substrate. Particular multi-part tooth whitening formulations using this principle and methods of use thereof are also provided.

Abstract: The present invention relates to a composition for dyeing keratin fibers, comprising: a) one or more liquid fatty substances; b) one or more amphoteric surfactants of formula (I) below: Ra—C(O)—NH—CH2—(CH2)n—N(B)(B?); in which: B represents the group —CH2—CH2—O—X?; B? represents the group —(CH2)zY?, with z=1 or 2; X? represents the group —CH2—C(O)OH, —CH2—C(O)OZ?, —CH2—CH2—C(O)OH or —CH2—CH2—C(O)OZ?, or a hydrogen atom; Y? represents the group —C(O)OH, —C(O)OZ?, —CH2—CH(OH)—SO3H or the group —CH2—CH(OH)—SO3—Z?; Z? and Z? represent, independently of each other, a cationic counterion derived from an alkali metal or alkaline-earth metal, such as sodium, an ammonium ion or an ion derived from an organic amine; Ra? represents a C10-C30 alkyl or alkenyl group derived from an acid Ra?—C(O)OH, which is preferably present in copra oil or in hydrolyzed linseed oil, an alkyl group, especially a C17 group and its iso form, or an unsaturated C17 group and n represents an integer ranging from 1 to 10 and preferably from 1

Abstract: A cosmetic product includes a cosmetic preparation including, in relation to the total weight thereof, 35 to 85 wt % polar solvent and 0.001 to 10 wt % oxidation dye precursor. The cosmetic product also includes b) a device for flash evaporation of the cosmetic preparation a). A method incorporates the use of the corresponding product and particularly the use of the cosmetic preparation a) as a process material in a device for flash evaporation.

Abstract: The present application relates to new compounds in the family of N-acylamino-amides having formula (I), compositions, in particular cosmetic compositions comprising them, and their use to treat the signs of aging of skin of the body or face, whether chronobiological or photo-induced, and in particular aging generated by reduced skin elasticity. in which p=1, 2 or 3 R independently denotes a cyano (—CN), hydroxy (—OH), CO2R? group in which R? denotes a hydrogen atom or linear or branched C1-C6 alkyl group, R1 denotes a hydrogen atom or a linear or branched C1-C6 alkyl group, and also the salts and/or isomers and/or solvates thereof.

Abstract: The invention relates to a cosmetic method for treating human body odors. Said method includes: (i) applying, to the skin, a composition containing a polymer (I): wherein R? is, separately, H or an acetyl grouping or a —CO-L-X grouping, the polymer containing at least one R??—CO-L-X grouping, L being a divalent hydrocarbon group containing 1 to 20 carbon atoms, X denoting a photoactive azide or diazirine group, and n ranging from 5 to 2000; then (ii) exposing the skin to visible light. The method used on the skin can also be used on materials for deodorizing malodorous environments such as shoe soles or clothing.

Abstract: A dentifrice composition having a low water phase comprising effective amounts of polyphosphate and ionic active ingredients. The composition comprises a source of metal ions, an inorganic phosphate salt having four or more phosphorus atoms and a cross-linked polyvinylpyrrolidone thickening agent in a single phase. Preferred metal ions are stannous, copper and zinc, in particular from zinc citrate and stannous fluoride.

Abstract: The application relates to oral care compositions comprising substantive polyesters formed from xylitol, polycarboxylic acids (or esters, acid halides or anhydrides thereof) and optionally arginine. The formed polyesters or polyesteramides are active in biofilm inhibition and dissolution to maintain clean teeth.

Abstract: Provided is a surface-treated powder, where at least one compound of general formula (1) adheres to the surface of the powder. In formula (1), R2 is a monovalent aromatic hydrocarbon group having 6-12 carbon atoms, R4 is a monovalent non-aromatic hydrocarbon group having 1-30 carbon atoms, R1 and R0 are a group selected from aforementioned groups defined for R2 and R4, and R3 is a group of formula (2), R5 is a divalent hydrocarbon group having 2 to 8 carbon atoms and R6 is an alkyl group having 1 to 6 carbon atoms, a, b, c, and d are integers of from 0-3, 0-200, 1-150, and 0-50, respectively, provided that when a is 0, d and e are integers of from 1-50 and 0-2, respectively, and c/(b+c+d) is 0.25 or more.

Abstract: The present invention relates to a cosmetic composition including an oil phase, a polyol phase, and a phase. The oil phase includes polysilicone-11, mixture of dimethicone, dimethicone crosspolymer and cetyl peg/ppg-10/1 dimethicone, ethylhexyl palmitate; and hyaluronic acid derivative. The polyol phase includes ascorbic acid, ascorbyl glucoside, propylene glycol, glycerin, and hydroxyethylpiperazine ethane sulfonic acid. The tertiary phase includes anogeissus leiocarpus bark extract. The cosmetic composition provides immediate soft focus effect and long term anti-wrinkle effect. The present invention also relates to a method of making the cosmetic composition.

Abstract: The present subject matter includes a product formulation made by the process including the steps of: adding a sufficient amount of water to cover a group of long grain seeds to form a first mixture; adding a sufficient amount of water to cover a group of whole grain seeds to form a second mixture; boiling the first and second mixtures, cooling the first mixture to form a thin colorless liquid; separating any solid seeds from the thin colorless liquid; cooling the second mixture to form an opaque thick liquid; separating any solid seeds from the opaque thick liquid; combining the thin colorless liquid and the opaque thick liquid to form a third mixture; cooling the third mixture to allow the formulation of a film; heating the film to form a porous material; cooling the porous material to form a powder residue; and processing the powder residue to form a formulation. The formulation can be used in various cosmetics, and to treat subject in need of treatment for skin conditions, such as acne.

Abstract: The present invention provides methods and kits for preventing, treating or delaying various cardiovascular diseases or disorders especially heart failure by extended release of neuregulin to a mammal. Moreover, the extended release of neuregulin is administered by subcutaneous infusion with a pump.

Abstract: A multi-step method of making a mammalian subcutaneous medical implant or non-implant for releasing self-contained drugs on a controlled basis over at least a 3 day period includes depositing at least portions of one or more individual layers of the implant by at least one computer controlled 3-D printer. The 3-D printing method may be accomplished via an array of 3-D nozzles that deposit materials (such as plastics, thermoplastics, coating materials, drug-containing matrix materials, non-drug containing matrix materials, bonding materials, biodegradable materials and/or the like) in very small, precise portions. The materials may be deposited in liquid, powder, sheet or other forms. Non-implant forms may also be provided by the techniques disclosed herein.

Abstract: The present invention generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye. The implant comprises a polymer layer and a silicone adhesive layer with a therapeutic agent interspersed therein and joined to the polymer layer. This implant is for placement in the sub-Tenon's space of the eye and provides sustained release of the therapeutic agent during the treatment or prevention of the disorder of the eye.

Abstract: Aerosol formulations comprising glycopyrronium bromide, formoterol or a salt thereof, and beclometasone dipropionate are useful for the prevention or treatment of moderate/severe chronic obstructive pulmonary disease.

Abstract: The invention relates to water-soluble granules for preparing a drinkable solution, in particular for preventing or treating symptoms associated with mild to moderate chronic venous insufficiency of the lower extremities, containing at least 20 percent by weight of a concentrated extract of red wine leaves, and to a ready-to-use packaging unit comprising one or more portion sachets which contain the granules according to the invention.

Abstract: The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

Abstract: The present invention relates to the development of two types of polymer nanocapsules to encapsulate cloxacillin benzathine, an antimicrobial drug. More specifically, this invention relates to a new form of treatment for mastitis in dairy cattle. Two nanocapsule formulations have been developed and can be used to encapsulate various drugs, besides cloxacillin benzathine, providing a new therapy for mastitis in cows, avoiding the inconvenience of the use of high doses of drugs used in conventional formulations, thus contributing to an improvement in milk quality.

Abstract: Provided is a bilayer membrane vesicle capable of undergoing a phase transition. The bilayer membrane vesicle includes: (a) a fatty acid salt having 6 to 20 carbon atoms; (b) an alcohol or an amine compound having an aliphatic chain of 6 to 20 carbon atoms; and (c) an artificial synthetic lipid or a phospholipid capable of forming a bilayer membrane. Preferably, this bilayer membrane vesicle further contains (d) a tertiary amine as a component of the membrane. Also provided is a method of inducing a phase transition of a bilayer membrane vesicle, the method including the step of adding a dehydrating condensing agent or a dehydrating condensing agent precursor having the property of accumulating at an interface to the bilayer membrane vesicle. By causing the lipids that form a molecular aggregate to chemically change, it is possible to change the physical property and the morphology of the molecular aggregate and control the timing of phase transitions such as membrane fusion.

Abstract: The invention relates to a method and a device for producing nanoparticles of organic substances, in particular by controlled expansion of pressurized solutions. The method comprises: admixing the organic substance and a supercritical fluid to form a mixture at a first pressure; decreasing the first pressure gradually to a second pressure so that a flow of the mixture is formed and nucleation of the organic substance in the mixture is initiated; and, decreasing the second pressure to a third pressure, so that solidification of the fluid of the mixture, comprising the nucleated organic substance, is initiated. The device comprises: a pressure chamber (1) for a mixture of the organic substance and a supercritical fluid; a collection chamber (5) for the nanoparticles; an outlet tube (2) connecting the pressure chamber to the collection chamber (5); and, one or more second nozzles (6).

Abstract: This invention relates to the field of pharmaceutical chemistry and, more specifically, to pharmaceutical formulations as well as to intermediates used to prepare such formulations and to methods for manufacturing such formulations.

Abstract: This invention relates to coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations. This invention further relates to methods of preparation and use of the systems, pharmaceutical compositions and preparations to treat persons having ADD, ADHD, autism, cystic fibrosis and other behavioral and neurological disorders.

Abstract: The invention provides a controlled release oral solid formulation comprising (a) a controlled release component comprising core comprising levodopa and/or an ester of levodopa or salts thereof, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric coated polymer; and (b) a decarboxylase inhibitor component.

Abstract: The disclosure provides bioactive agent-containing particulates that include bioactive agent, biocompatible polymer, negatively charged groups, and a cationic agent. The particulates can be associated with a medical device, such as a balloon catheter, which can be used to move the particulates to a treatment site. Transfer of the particulates from the device to tissue is facilitated by the arrangement of the cationic and bioactive agent-containing particulates.

Abstract: Intact, bacterially-derived minicells can safely introduce therapeutically effective amounts of plasmid-free functional nucleic acid to target mammalian cells. To this end, functional nucleic acid can be packaged into intact minicells directly, without resort to expression constructs, the expression machinery of the host cell, harsh chemicals or electroporation.

Abstract: A method for treating a patient having one or more of anxiety, hypersensitivity, restricted areas of interest, repetitive behaviors, irritability and emotional lability, or otherwise requiring a calming effect, is disclosed. The method includes administering to the patient a plurality of comestible units, e.g., cookies, cumulatively comprising a therapeutically effective amount of inositol.

Abstract: Compounds of the formulae and selected hindered nitroxyl, hydroxylamine and hydroxylamine salt compounds such as the compound of the formula wherein G1 is hydrogen; C1-C22alkyl; C1-C22alkylthio; C2-C22alkylthioalkyl; C5-C7cycloalkyl; phenyl; C7-C9-phenylalkyl; or SO3M; G2 is C1-C22alkyl; C5-C7cycloalkyl; phenyl; or C7-C9-phenylalkyl; E is oxyl or hydroxyl; V is —O—; or —NH—; a is 0 or 1 or 2; b, c and d and g are each independently of one another 0 or 1; e is an integer from 1 to 4; f, m, n and p are each independently of one another an integer from 1 to 3; q is 0 or an integer from 1 to 3; Q, T and G3 are as defined in claim 1; G4 and G5 are each independently of the other hydrogen; or C1-C22alkyl; exhibit marked antiinflammatory action.

Abstract: A pharmaceutical formulation for treatment of shingles is provided. The formulation includes between 0.2 mg of menthol per 120 mL of the formulation and 1.0 mg of menthol per 120 mL of the formulation, camphor water, lime water, and a local anesthetic. The local anesthetic includes one of between 0.6 mL of phenol per 120 mL of the formulation and 2.0 mL of phenol per 120 mL of the formulation and between 0.25% concentration by weight of lidocaine and 5% concentration by weight of lidocaine.

Abstract: A method for treating a cancer includes administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising Monobenzone or a pharmaceutical acceptable salt thereof. The cancer is selected from pleural-related cancer, abdominal-related cancer, endocrine-related cancer, gastrointestinal tract-related cancer, osteosarcoma, and skin cancer. The pleural-related cancer is lung cancer. The abdominal-related cancer is selected from bladder cancer, cervical cancer, and kidney cancer. The endocrine-related cancer is selected from prostate cancer, breast cancer, and ovarian cancer. The gastrointestinal tract-related cancer is selected from gastric cancer, hepatic cancer, colorectal cancer, pancreatic cancer, and tongue cancer.

Abstract: Disclosed are a composition for preventing and treating atherosclerosis which includes chalcone compound. In particular, the chalcone compound bound with 2-hydroxyl in ring A and 4?-methyoxy in ring B has versatile therapeutic potentials on anti-atherosclerosis by acting as PPAR? inducer, p44/42 MAPK inhibitor and cell cycle blocker and does not show toxicity to human aortic smooth muscle cells (HASMCs). In addition, the chalcone compound exhibits synergistic effect with the PPAR? ligand (rosiglitazone) to inhibit cell proliferation and the upregulation of cyclin D1, cyclin D3, interleukin-1? (IL-1?) and interleukin-6 (IL-6) induced by oxidized low density lipoprotein (Ox-LDL).

Abstract: The present invention is directed to method for the treatment of depression, for example, treatment resistant depression; wherein the treatment regimen is adjusted depending on the patient's genotype at SNP rs4306882.

Abstract: The present invention relates to a composition comprising an ASM inhibitor as an active ingredient for preventing or treating degenerative neurological diseases. According to the present invention, when ASM is partially removed in an Alzheimer's disease model mouse, that is when ASM is inhibited therein, such when as an Alzheimer's disease model mouse with a partial removal of ASM is in a parabionic union with an Alzheimer's disease model mouse, or when an Alzheimer's disease model mouse is injected with the serum of an Alzheimer's disease model mouse from which ASM gene has been removed, the deposition of ?-amyloid in the brain tissue is inhibited and the ability to learn and remember are improved, and the present invention confirms such superb effects. Accordingly, ASM inhibitor can be effectively used to prevent or treat degenerative neurological diseases.

Abstract: A combination of dosage units for alleviating respiratory ailments and a method of alleviating respiratory ailments which uses this combination of dosage units. The dosage units comprise one or more first dosage units comprising pseudoephedrine and/or a pharmaceutically acceptable salt thereof and one or more second dosage units comprising phenylephrine and/or a pharmaceutically acceptable salt thereof.

Abstract: Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1? in the wound.

Abstract: An aqueous loxoprofen-containing patch is provided, which has good stability and excellent transdermal absorption of loxoprofen. The aqueous patch includes loxoprofen or a salt thereof and triacetin. Specifically, the aqueous patch includes, based on the weight of the adhesive gel base, 0.1 to 5% by weight of loxoprofen or a salt thereof, 0.5 to 5% by weight of triacetin, 1 to 30% by weight of a water-soluble polymer, 0.01 to 5% by weight of a cross-linking agent, 10 to 90% by weight of purified water, and 0 to 20% by weight of an inorganic powder.

Abstract: Disclosed herein are cocrystals of p-coumaric acid and nicotinamide. A 1:1 molar ratio and a 2:1 molar ratio of p-coumaric acid to nicotinamide are herein disclosed.

Abstract: Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.

Abstract: The present invention relates to a pharmaceutical composition comprising a sodium benzoate compound and clozapine; and a method for preventing, treating and/or reducing the risk of a neuropsychiatric disorder by administering such pharmaceutical composition.

Abstract: Pharmaceutical compositions of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone and pharmaceutically acceptable salts thereof are described as well as methods of their use.

Abstract: Described herein are pharmaceutical compositions comprising one or more fumarate esters, processes for making the same, and compositions and methods for treating multiple sclerosis subjects with the compositions. In particular, oral pharmaceutical compositions comprising fumarate esters in liquid vehicles are described. One embodiment is an oral delayed release pharmaceutical dosage form comprising a soft capsule encapsulating an immediate releasing liquid comprising one or more fumarate esters.

Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.

Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of taxane-based compounds and/or fluorinated forms thereof. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the taxane-based compound is achieved.